News & Articles

The new inhalers would have near-zero Global Warming Potential propellant

First clinical trial injecting naked mRNA directly into the heart of patients undergoing elective coronary artery bypass surgery

DAPA-CKD Phase III trial sub-analyses showed that kidney and cardiovascular outcomes were consistent

Under the new agreement, unique SAGAsafe dPCR assays will be developed for the analysis of tissue samples and liquid biopsies

AstraZeneca will invest in VaxEquity, an Imperial College spin-off

Real-world data demonstrated 92% vaccine effectiveness against hospitalisations due to the Delta variant

Approval based on unprecedented results from the ADAURA Phase III trial where Tagrisso reduced the risk of disease recurrence or death by 80%

The monthly safety report will be made public on the European Medicines Agency website

Emergency Use Listing granted to AstraZeneca and Serum Institute of India enabling global access to the vaccine

Working with the UK government, first vaccinations are to begin early in the new year

HALIX to provide large-scale GMP manufacture of AZD1222

Two different dosing regimens demonstrated efficacy with one showing a better profile

AstraZeneca anticipates entering clinical development in 2021

First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination

Nirsevimab is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose

Interim data shows strong antibody and T-cell responses in all evaluated participants

Company exploring further additional global capacity to provide broad and equitable access

Collaboration will enable global development, manufacturing and distribution of the vaccine

The collaboration aims to develop novel, targeted treatments to address significant unmet needs

Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds.

Collaboration to look into link between epigenetics and respiratory disease

MEDI8852 blocked all influenza A with unique binding properties